Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine

Review

(2696) Views  (607) Full article downloads

Authors: Menno T Pruijm, Marc P Maillard, Michel Burnier

Published Date November 2008 Volume 2008:4(6) Pages 1159 - 1166

DOI: http://dx.doi.org/10.2147/VHRM.S3510

Menno T Pruijm, Marc P Maillard, Michel Burnier

Service of Nephrology and Hypertension, Department of Medicine, University Hospital, Lausanne, Switzerland

Abstract: Despite the development of many effective antihypertensive drugs, target blood pressures are reached in only a minority of patients in clinical practice. Poor adherence to drug therapy and the occurrence of side effects are among the main reasons commonly reported by patients and physicians to explain the poor results of actual antihypertensive therapies. The development of new effective antihypertensive agents with an improved tolerability profile might help to partly overcome these problems. Lercanidipine is an effective dihydropyridine calcium channel blocker of the third generation characterized by a long half-life and its lipophylicity. In contrast to first-generation dihydropyridines, lercanidipine does not induce reflex tachycardia and induces peripheral edema with a lower incidence. Recent data suggest that in addition to lowering blood pressure, lercanidipine might have some renal protective properties. In this review we shall discuss the problems of drug adherence in the management of hypertension with a special emphasis on lercanidipine.

Keywords: compliance, hypertension, calcium antagonists

Other articles by Dr Michel Burnier